2026 ICD-10-CM Diagnosis Code C91.A1Mature B-cell leukemia Burkitt-type, in remission
ICD-10-CM Codes›C00–D49›C81-C96›C91
- Billable — Valid for Submission
- Chronic Condition
C91.A1 is a billable ICD-10-CM diagnosis code for mature B-cell leukemia Burkitt-type, in remission. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Leukemia in remission.
Code Identity
Code Classification
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Lymphoma
Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C91.A1 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C91.A1Overview
Is C91.A1 (Mature B-cell leukemia Burkitt-type) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report mature B-cell leukemia Burkitt-type, in remission on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C91.A1 group to?
When mature B-cell leukemia Burkitt-type, in remission is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C91.A1?
Under the General Equivalence Mappings, mature B-cell leukemia Burkitt-type, in remission converts to ICD-9-CM 204.81 (oth lym leuk w rmsion). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
